# Indiana University clinical Center for acute pancreatitis and diabetes clinical research network

> **NIH NIH U01** · INDIANA UNIVERSITY INDIANAPOLIS · 2020 · $278,416

## Abstract

PROJECT SUMMARY / ABSTRACT
Pancreatogenic diabetes, or type 3c diabetes (T3cDM), is a known complication of acute pancreatitis (AP).
Recent data suggest that T3cDM occurs more commonly than previously recognized and exhibits a spectrum of
defects including features that overlap aspects of both type 1 and type 2 diabetes. At present, the extent to which
immune activation, β cell dysfunction, and insulin resistance occur following AP and the genetic, metabolic and
imaging correlates of these phenotypes have not been characterized. To address these knowledge gaps, we
have assembled a multidisciplinary team with expertise in pancreatitis and exocrine pathophysiology, diabetes,
β cell biology, diabetes genetics, and pancreatic imaging at the Indiana University School of Medicine. The IU
Clinical Center will work with other members of the Type 1 Diabetes in Acute Pancreatitis Consortium to test the
hypothesis that T3cDM encompasses a heterogeneous combination of metabolic and potentially immunologic
phenotypes that are determined by distinct underlying pathophysiologies. We propose the following specific aims
(SA) to meet the goals of this RFA. SA #1: To perform an observational study of robustly characterized adults
with AP in order to address knowledge gaps in the natural history and incidence of autoantibody-positive diabetes
(AAb+), impaired glucose tolerance (IGT)/impaired fasting glucose (IFG), and diabetes occurring subsequent to
AP. Enrolled participants will be longitudinally characterized with emphasis on identifying genetic, immunological,
metabolic, and clinical risk factors for the development of AAb+, IGT/IFG, or T3cDM. We will use state-of-the-art
immunologic phenotyping and measurements of pancreatic β cell function to define the physiologic basis for
metabolic dysregulation in T3cDM after AP. In tandem, a biorepository will be developed for undertaking
translational, mechanistic and biomarker investigations and ancillary studies. SA#2: The Imaging Morphology of
Pancreas in Diabetic Patients following Acute Pancreatitis (IMMINENT) study aims to utilize novel quantitative
magnetic resonance imaging techniques as a non-invasive biomarker to identify patients at risk for the
development of post-AP T3cDM. This longitudinal study will evaluate pancreatic parenchymal morphologic and
pathophysiologic changes following AP in AAb+, euglycemic, IGT and DM individuals. Imaging phenotypes will
be correlated with the metabolic, genetic and immunological phenotypes established in SA#1. SA#3: To perform
a nested case control study using state-of-the-art techniques to define the underlying pathophysiology of
endocrine and exocrine function in the subgroup of AAb+ individuals with AP-associated metabolic dysfunction
relative to those who remain normoglycemic. We will undertake detailed metabolic phenotyping to evaluate islet
cell responses (i.e. β and alpha cell function) in parallel with arginine-augmented hyperglycemic clamp
methodology to measure fun...

## Key facts

- **NIH application ID:** 10127104
- **Project number:** 1U01DK127382-01
- **Recipient organization:** INDIANA UNIVERSITY INDIANAPOLIS
- **Principal Investigator:** Carmella Evans-Molina
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $278,416
- **Award type:** 1
- **Project period:** 2020-09-17 → 2025-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10127104

## Citation

> US National Institutes of Health, RePORTER application 10127104, Indiana University clinical Center for acute pancreatitis and diabetes clinical research network (1U01DK127382-01). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10127104. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*